KING OF PRUSSIA, Pa.--(Business Wire)--
Trevena Inc., a biotechnology company focused on discovery of a new generation
of drugs that target G-protein coupled receptors, announced today that
BusinessWeek magazine included Trevena in its list of most successful US startup
companies of 2008. The complete list of companies is available in the December
19th, 2008 edition of BusinessWeek, and can be found at
http://images.businessweek.com/ss/08/12/1217_hottest_startups/1.htm
About Trevena, Inc.
Trevena Inc. is a Philadelphia-based drug discovery company focused on
developing pharmaceutical products targeting G-protein coupled receptors
(GPCRs). Pharmaceutical products that target GPCRs represent over 40% of
marketed drugs today. Trevena`s drug discovery platform, licensed from Duke
University Medical Center, is based on extensive research from the laboratories
of scientists Robert J. Lefkowitz, M.D. and Howard A. Rockman, M.D. The
company`s drug discovery portfolio is currently focused on programs for
cardiovascular and CNS indications. Trevena is privately held, and current
investors are Alta Partners, Healthcare Ventures, New Enterprise Associates and
Polaris Venture Partners. (www.trevenainc.com)
Trevena Inc.
Alastair Southwell, 610-354-8840
asouthwell@trevenainc.com
Copyright Business Wire 2009
